Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 116 matching trials from the live ClinicalTrials.gov search.
Recruiting Not applicable Interventional Accepts healthy volunteers

Mindfulness for Cognition in Early-stage Alzheimer's Disease

NCT06792877
Conditions
Mild Cognitive Impairment (MCI), Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, TBI (Traumatic Brain Injury), Aging, Healthy Elderly, Alzheimer&Amp;Amp;#39;s Dementia (AD)
Interventions
Mindfulness Intervention, Waitlist then mindfulness
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation

NCT06234930
Conditions
Healthy Aging, Alzheimer's Disease
Interventions
Audiovisual stimulation VR system
Device
Lead sponsor
Clarity Health Technologies, Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Portola Valley, California • Leesburg, Florida
Completed No phase listed Observational Accepts healthy volunteers

Bilateral Brain Dynamics in Cognition and Aging

NCT03224988
Conditions
Alzheimer Disease, Aging, MCI
Interventions
TMS
Device
Lead sponsor
Duke University
Other
Eligibility
60 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment
Interventions
COT, Sham
Drug
Lead sponsor
Evon Medics LLC
Industry
Eligibility
55 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia
Completed Phase 2 Interventional Results available

Metformin in Amnestic Mild Cognitive Impairment

NCT00620191
Conditions
Mild Cognitive Impairment
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Microbiome in Aging of Gut and Brain

NCT07799402
Conditions
Mild Cognitive Impairment, Alzheimer Disease (AD), Dementia
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Terminated Not applicable Interventional Accepts healthy volunteers

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

NCT04294888
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Aging
Interventions
repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive-Motor Training for AD/ADRD Prevention

NCT07160582
Conditions
MCI, Aging
Interventions
Novel CogXergaming Training, Exercise and Education Training Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Interventions
human Mesenchymal Stem Cells
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
Interventions
Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
Biological
Lead sponsor
Steven E Arnold, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Conditions
Mild Cognitive Impairment, Alzheimer Dementia
Interventions
CpG1018, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer's Disease
Interventions
Placebo, Bepranemab
Other · Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
50 Years to 80 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Fresno, California • Fullerton, California • Irvine, California + 34 more
Not listed No phase listed Observational Accepts healthy volunteers

Evolution of Memory Related Activity

NCT00902499
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Alzheimer Disease, Mild Alzheimer Disease, MCI With Increased Risk for Alzheimer Disease, Cognitive Impairment, Mild
Interventions
Siponimod, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
50 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Mild Cognitive Impairment, Alzheimer Disease 1
Interventions
Aducanumab, Exablate Model 4000 Type 2, Lecanemab
Drug · Device
Lead sponsor
Ali Rezai
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Morgantown, West Virginia
Completed Not applicable Interventional Results available

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667
Conditions
Mild Cognitive Impairment
Interventions
APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Conditions
Alzheimer Disease
Interventions
Donepezil, Vitamin E
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more
Conditions
Cognitive Impairment, Alzheimer Blood Biomarkers, Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Interventions
Multimodal Lifestyle Intervention
Behavioral
Lead sponsor
HudsonAlpha Institute for Biotechnology
Other
Eligibility
65 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts